The randomized, double-blind, placebo-controlled Phase 2b VITAL trial enrolled 91 patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer
The trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the combination therapy
Approval marks Venus Remedies’ first anti-infective marketing authorization in Indonesia and enables the country’s first generic entry for this critical antibiotic combination
UNLOXCYT is an evolution in checkpoint inhibition and is now available for the treatment of adults in the U.S. with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation
The updated closure system introduces intuitive handling, innovative functionality and a premium design compatible with a wide range of syringe formats
The partnership aims to fuse Avantium’s breakthrough materials with Packamama’s expertise in low-emission, innovative wine bottles
Experts caution that realizing AI’s potential requires careful management and risk mitigation
The feature will be available across all Max Healthcare facilities, offering patients consistent and convenient access to services nationwide
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
Subscribe To Our Newsletter & Stay Updated
